Compare Stocks: COCP, ICCC, ALDX, and FBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.36 -1.4%	$1.57	$1.07 ▼ $5.93	$82.04M	1.2	1.78 million shs	366,921 shs
COCP Cocrystal Pharma	$1.18 +3.9%	$1.06	$0.76 ▼ $2.03	$22.81M	1.48	894,179 shs	176,481 shs
FBIO Fortress Biotech	$2.51	$2.94	$2.18 ▼ $4.53	$83.71M	1.19	669,384 shs	414,674 shs
ICCC ImmuCell	$9.95 -0.3%	$10.48	$4.52 ▼ $12.10	$90.35M	0.54	24,639 shs	10,036 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+0.73%	-5.48%	-10.97%	-29.59%	-71.84%
COCP Cocrystal Pharma	0.00%	-7.32%	+5.56%	+14.57%	-6.17%
FBIO Fortress Biotech	+2.03%	-2.33%	-13.75%	-16.05%	-27.03%
ICCC ImmuCell	+3.85%	+0.71%	+2.25%	+5.16%	+76.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.36 -1.4%	$1.57	$1.07 ▼ $5.93	$82.04M	1.2	1.78 million shs	366,921 shs
COCP Cocrystal Pharma	$1.18 +3.9%	$1.06	$0.76 ▼ $2.03	$22.81M	1.48	894,179 shs	176,481 shs
FBIO Fortress Biotech	$2.51	$2.94	$2.18 ▼ $4.53	$83.71M	1.19	669,384 shs	414,674 shs
ICCC ImmuCell	$9.95 -0.3%	$10.48	$4.52 ▼ $12.10	$90.35M	0.54	24,639 shs	10,036 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+0.73%	-5.48%	-10.97%	-29.59%	-71.84%
COCP Cocrystal Pharma	0.00%	-7.32%	+5.56%	+14.57%	-6.17%
FBIO Fortress Biotech	+2.03%	-2.33%	-13.75%	-16.05%	-27.03%
ICCC ImmuCell	+3.85%	+0.71%	+2.25%	+5.16%	+76.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	304.41% Upside
COCP Cocrystal Pharma	1.00	Sell	N/A	N/A
FBIO Fortress Biotech	2.25	Hold	$17.00	577.29% Upside
ICCC ImmuCell	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest COCP, ICCC, ALDX, and FBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/14/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/17/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/14/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/8/2026	FBIO Fortress Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/2/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
COCP Cocrystal Pharma	$330K	69.11	N/A	N/A	$0.46 per share	2.57
FBIO Fortress Biotech	$63.26M	1.32	N/A	N/A	$2.00 per share	1.26
ICCC ImmuCell	$27.64M	3.27	$0.20 per share	49.85	$2.99 per share	3.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	11/4/2026 (Estimated)
COCP Cocrystal Pharma	-$8.83M	-$0.76	N/A	N/A	N/A	N/A	-207.47%	-123.33%	11/13/2026 (Estimated)
FBIO Fortress Biotech	$6.82M	$2.64	0.95	N/A	N/A	163.32%	83.47%	42.98%	11/16/2026 (Estimated)
ICCC ImmuCell	-$1.04M	$0.08	124.39	N/A	N/A	2.57%	2.69%	1.76%	11/12/2026 (Estimated)

Latest COCP, ICCC, ALDX, and FBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	COCP Cocrystal Pharma	-$0.17	-$0.23	-$0.06	-$0.23	$0.11 million	$0.11 million
8/13/2026	Q2 2026	FBIO Fortress Biotech	-$0.20	-$0.08	+$0.12	-$0.08	$18.30 million	$18.72 million
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
COCP Cocrystal Pharma	N/A	1.24	1.24
FBIO Fortress Biotech	0.17	3.96	3.83
ICCC ImmuCell	0.22	4.75	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
COCP Cocrystal Pharma	6.72%
FBIO Fortress Biotech	96.51%
ICCC ImmuCell	13.47%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
COCP Cocrystal Pharma	39.40%
FBIO Fortress Biotech	28.50%
ICCC ImmuCell	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	6	60.33 million	53.21 million	Optionable
COCP Cocrystal Pharma	10	19.26 million	11.67 million	Not Optionable
FBIO Fortress Biotech	78	33.35 million	23.85 million	Optionable
ICCC ImmuCell	73	9.08 million	8.56 million	Not Optionable

COCP, ICCC, ALDX, and FBIO Headlines

Recent News About These Companies

Spero Therapeutics (NASDAQ:SPRO) vs. ImmuCell (NASDAQ:ICCC) Head-To-Head Comparison

September 18 at 6:18 AM | americanbankingnews.com

ImmuCell (NASDAQ:ICCC) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

September 9, 2026 | marketbeat.com

ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average - What's Next?

September 1, 2026 | marketbeat.com

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2

August 27, 2026 | zacks.com

ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

August 22, 2026 | marketbeat.com

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

August 13, 2026 | finance.yahoo.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

August 13, 2026 | globenewswire.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

August 6, 2026 | globenewswire.com

ImmuCell: First Defense With Better Execution

July 24, 2026 | seekingalpha.com

ImmuCell posts strong preliminary Q2 sales on US demand

July 11, 2026 | msn.com

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

July 10, 2026 | zacks.com

ImmuCell reports preliminary Q2 sales increase of 11.5% to $7.2M

July 9, 2026 | msn.com

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

July 9, 2026 | globenewswire.com

Insider Buying: ImmuCell (NASDAQ:ICCC) CEO Acquires $75,920.00 in Stock

June 23, 2026 | insidertrades.com

ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

June 18, 2026 | zacks.com

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

May 25, 2026 | zacks.com

ImmuCell (ICCC) Q1 2026 Earnings Transcript

May 17, 2026 | aol.comA

ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth

May 17, 2026 | finance.yahoo.com

ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript

May 15, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP, ICCC, ALDX, and FBIO Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$1.36 -0.02 (-1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 -0.01 (-0.37%)

As of 06:14 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Cocrystal Pharma NASDAQ:COCP

$1.18 +0.04 (+3.86%)

Closing price 03:59 PM Eastern

Extended Trading

$1.21 +0.03 (+2.11%)

As of 05:59 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Fortress Biotech NASDAQ:FBIO

$2.51 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.58 +0.07 (+2.79%)

As of 06:04 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

ImmuCell NASDAQ:ICCC

$9.95 -0.03 (-0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$9.90 -0.04 (-0.45%)

As of 04:10 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COCP, ICCC, ALDX, and FBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COCP, ICCC, ALDX, and FBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COCP, ICCC, ALDX, and FBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP, ICCC, ALDX, and FBIO Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Cocrystal Pharma NASDAQ:COCP

Fortress Biotech NASDAQ:FBIO

ImmuCell NASDAQ:ICCC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COCP, ICCC, ALDX, and FBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COCP, ICCC, ALDX, and FBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COCP, ICCC, ALDX, and FBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP, ICCC, ALDX, and FBIO Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Cocrystal Pharma NASDAQ:COCP

Fortress Biotech NASDAQ:FBIO

ImmuCell NASDAQ:ICCC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools